Why gene editing isn’t ready for treating human disease: It’s not ‘efficient enough’

gene editing
Image: New York Times/Lily Padula

Gene editing will likely always come with a bit of risk; when you’re cutting and pasting DNA in millions of cells, extremely rare events can’t be avoided.

In the new work, spread across three papers, researchers tackle two genetic diseases that seem to tick most of the boxes for “worth the risk.” The disease are Duchenne muscular dystrophy (DMD) and Hutchinson–Gilford progeria syndrome (HGPS).


If these are the sorts of disorders we could treat with gene editing, how close are we to doing so? To find out, researchers decided to test out the systems in mice.

Overall, the three papers present a consistent picture. The technology works, it’s possible to fix genetic defects through gene editing, and the fixes can have an effect on health. But the editing isn’t currently efficient enough to provide anything more than some partial help for people with these diseases. And that help comes with some significant risks: errors in editing, activity in the wrong cells, and an immune response that limits future interventions. We’ve got a lot of work ahead of us before this is ready for the clinic.

Related article:  CRISPR creates 'smart' hydrogels that could lead to therapies capable of fighting multiple infections, diseases

Read full, original post: Gene editing still has a few bugs in the system

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Deaths from COVID-19 are far higher than reported estimates

Infographic: Deaths from COVID-19 are far higher than reported estimates

More than 2.8 million people have lost their lives due to the pandemic, according to a Wall Street Journal analysis ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend